HIV Disease Progression

Prednisolone

Bugando Medical Center

Progression of HIV-Disease Under Low Dose Corticosteroids

A Phase II Clinical Trial to Assess Risk and Benefit of Oral Low Dose Prednisolone for HIV Infected People Prior to the Commencement of Antiretroviral Treatment

The primary objective of the study is to assess the effect of the low dose prednisolone therapy on the time to progression of HIV disease. The time to progression is defined as the time between the baseline and the change of staging to advanced disease (CDC stage A3, B3 or C) or death

The total CD4 cell count, measured in number of cells per µl, should be significantly higher in the intervention group.

The rate of survival should not differ significantly between the two groups.

The quality of life of participants, as measured by a standardised set of questions, should not differ significantly between the two groups.

The rate of co-infections should not be significantly higher in the intervention group.

In vitro studies on isolated lymphocytes of patients in both arms should show significant differences in their activation status.

Dr. August Stich

MD, MSc

Medical Mission Institute, Germany

German Leprosy and Tuberculosis Relief Association

University of Wuerzburg

Action Medeor

herpes simplex/phosphatase

Progression of HIV-Disease Under Low Dose Corticosteroids

Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)

کاملترین پایگاه داده گیاهان دارویی با پشتیبانی علمی